Polfurmetinib
Based on 1 publication(s) in Google Scholar
Polfurmetinib (MEK-IN-6) is a MEK inhibitor and inhibits ERK1/2 phosphorylation in A375 cells. Polfurmetinib can be used for cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.28%
- CAS No.: 2845151-86-0
- Formule: C18H20FN3O4S
- Masse moléculaire:393.43
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-50846
SCH772984ERK1/2 Inhibitor -
HY-12058
AZD8330MEK Inhibitor -
HY-14691
RefametinibMEK1/MEK2 Inhibitor -
HY-15437
SL327MEK Inhibitor -
HY-15202
BinimetinibMEK1/2 Inhibitor -
HY-15610
GDC-0623MEK1 Inhibitor -
HY-14719
RO4987655MEK Inhibitor -
HY-13064
CobimetinibMEK1 Inhibitor -
HY-13449
TAK-733MEK Inhibitor -
HY-10999A
Trametinib (DMSO solvate)MEK Inhibitor -
HY-10174
PD184161MEK Inhibitor -
HY-19696
TauroursodeoxycholateEndoplasmic Reticulum Stress Inhibitor
Publications Citing Use of MedChemExpress (MCE) Polfurmetinib
MoreVoir tous les produits spécifiques à Isoform MEK
More
Activité biologique
Description
IC50 & Target
[1]|
MEK |
ERK1 |
ERK2 |
In Vitro
Polfurmetinib (Compound 69) inhibits ERK1/2 phosphorylation in A375 cells with IC50 = 2 nM[1].
Polfurmetinib exhibits high membrane permeability with a Papp = 19.6 × 10‑6 cm/s and an efflux ratio of 2.3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2845151-86-0
-
Appearance Solid
-
Masse moléculaire 393.43
-
Formule C18H20FN3O4S
-
Color White to light yellow
-
SMILES
O=C1C=C2C(C(N(CC2)OCCO)=O)=C(N1C)NC3=CC=C(C=C3F)SC
-
Synonyms
MEK-IN-6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Guggulsterone suppresses osteosarcoma progression by inhibiting glycolysis through MAPK signaling pathway. [Abstract]2025 Aug:144:156949. PMID: 40517691
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (254.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5417 mL | 12.7087 mL | 25.4175 mL | 63.5437 mL |
| 5 mM | 0.5083 mL | 2.5417 mL | 5.0835 mL | 12.7087 mL | |
| 10 mM | 0.2542 mL | 1.2709 mL | 2.5417 mL | 6.3544 mL | |
| 15 mM | 0.1694 mL | 0.8472 mL | 1.6945 mL | 4.2362 mL | |
| 20 mM | 0.1271 mL | 0.6354 mL | 1.2709 mL | 3.1772 mL | |
| 25 mM | 0.1017 mL | 0.5083 mL | 1.0167 mL | 2.5417 mL | |
| 30 mM | 0.0847 mL | 0.4236 mL | 0.8472 mL | 2.1181 mL | |
| 40 mM | 0.0635 mL | 0.3177 mL | 0.6354 mL | 1.5886 mL | |
| 50 mM | 0.0508 mL | 0.2542 mL | 0.5083 mL | 1.2709 mL | |
| 60 mM | 0.0424 mL | 0.2118 mL | 0.4236 mL | 1.0591 mL | |
| 80 mM | 0.0318 mL | 0.1589 mL | 0.3177 mL | 0.7943 mL | |
| 100 mM | 0.0254 mL | 0.1271 mL | 0.2542 mL | 0.6354 mL |
Polfurmetinib Related Classifications
HY-153445 Related Classifications
Powered by Bioz